Brief: Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 Trial Evaluating Oral LUM-201 in PGHD
11/04/2022 15:54
April 11 (Reuters) - Lumos Pharma Inc LUMO.O :
* LUMOS PHARMA REACHES 50% RANDOMIZATION MILESTONE IN PHASE
2
ORAGROWTH210 TRIAL EVALUATING ORAL LUM-201 IN PGHD
* LUMOS PHARMA INC - INTERIM DATA ANTICIPATED BY END OF 2022
* LUMOS PHARMA INC - INTERIM DATA FROM PK/PD ORAGROWTH212
TRIAL
ALSO ANTICIPATED BY END OF 2022
* LUMOS PHARMA INC - COMPLETE SET OF 6-MONTH, PRIMARY
OUTCOME DATA
FOR ORAGROWTH210 TRIAL IS ANTICIPATED IN SECOND HALF OF 2023
Source text for Eikon: ID:nGNX70FnSJ
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)